GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Capex-to-Operating-Income

China National Accord Medicines (SZSE:000028) Capex-to-Operating-Income : 0.14 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

China National Accord Medicines's Capital Expenditure for the three months ended in Mar. 2024 was ¥-71.91 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥526.51 Mil.

Hence, China National Accord Medicines's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.14.


China National Accord Medicines Capex-to-Operating-Income Historical Data

The historical data trend for China National Accord Medicines's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Capex-to-Operating-Income Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.15 0.17 0.13 0.13

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.13 0.13 0.14 0.14

Competitive Comparison of China National Accord Medicines's Capex-to-Operating-Income

For the Medical Distribution subindustry, China National Accord Medicines's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines's Capex-to-Operating-Income Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's Capex-to-Operating-Income falls into.



China National Accord Medicines Capex-to-Operating-Income Calculation

China National Accord Medicines's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-322.208) / 2499.36
=0.13

China National Accord Medicines's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-71.905) / 526.506
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


China National Accord Medicines Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines